Top-Rated StocksTop-RatedNASDAQ:XENE Xenon Pharmaceuticals (XENE) Stock Forecast, Price & News $35.17 -0.59 (-1.65%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$35.05▼$36.0350-Day Range$35.07▼$39.7352-Week Range$31.79▼$43.75Volume267,832 shsAverage Volume368,663 shsMarket Capitalization$2.26 billionP/E RatioN/ADividend YieldN/APrice Target$52.40 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Xenon Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.09 Rating ScoreUpside/Downside49.0% Upside$52.40 Price TargetShort InterestBearish4.33% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.62Based on 7 Articles This WeekInsider TradingSelling Shares$967,500 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.89) to ($3.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.03 out of 5 starsMedical Sector490th out of 968 stocksPharmaceutical Preparations Industry213th out of 445 stocks 3.5 Analyst's Opinion Consensus RatingXenon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.09, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $52.40, Xenon Pharmaceuticals has a forecasted upside of 49.0% from its current price of $35.17.Amount of Analyst CoverageXenon Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.33% of the outstanding shares of Xenon Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverXenon Pharmaceuticals has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Xenon Pharmaceuticals has recently increased by 2.21%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldXenon Pharmaceuticals does not currently pay a dividend.Dividend GrowthXenon Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for XENE. Previous Next 3.1 News and Social Media Coverage News SentimentXenon Pharmaceuticals has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Xenon Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest6 people have searched for XENE on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows4 people have added Xenon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xenon Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $967,500.00 in company stock.Percentage Held by InsidersOnly 5.43% of the stock of Xenon Pharmaceuticals is held by insiders.Percentage Held by Institutions95.70% of the stock of Xenon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($2.89) to ($3.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xenon Pharmaceuticals is -14.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xenon Pharmaceuticals is -14.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXenon Pharmaceuticals has a P/B Ratio of 3.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Xenon Pharmaceuticals (NASDAQ:XENE) StockXenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.Read More XENE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XENE Stock News HeadlinesSeptember 21, 2023 | americanbankingnews.comXenon Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:XENE)September 20, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: GoHealth (GOCO) and Xenon (XENE)September 22, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.September 16, 2023 | americanbankingnews.comXenon Pharmaceuticals (NASDAQ:XENE) Upgraded by StockNews.com to SellSeptember 14, 2023 | finance.yahoo.comXenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry SummitSeptember 12, 2023 | finance.yahoo.comXenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive DisorderSeptember 12, 2023 | finance.yahoo.comXenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive DisorderSeptember 4, 2023 | finance.yahoo.comXenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy CongressSeptember 22, 2023 | The Oxford Club (Ad)Better Than Oil Stocks?The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. August 31, 2023 | finance.yahoo.comXenon Pharmaceuticals to Present at the Wells Fargo 2023 Healthcare ConferenceAugust 22, 2023 | nasdaq.comCantor Fitzgerald Reiterates Xenon Pharmaceuticals (XENE) Overweight RecommendationAugust 13, 2023 | msn.comXenon Is Well-Funded Heading Into Key ReadoutsAugust 11, 2023 | finance.yahoo.comWall Street Analysts Believe Xenon Pharmaceuticals (XENE) Could Rally 36.75%: Here's is How to TradeAugust 11, 2023 | finanznachrichten.deXenon Pharmaceuticals Inc.: Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 11, 2023 | msn.comWedbush Reiterates Xenon Pharmaceuticals (XENE) Outperform RecommendationAugust 9, 2023 | finance.yahoo.comXenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 9, 2023 | finance.yahoo.comCompanies Like Xenon Pharmaceuticals (NASDAQ:XENE) Are In A Position To Invest In GrowthAugust 8, 2023 | markets.businessinsider.comHere's what Wall Street expects from Xenon Pharmaceuticals's earningsAugust 8, 2023 | financialpost.comXenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin GoverAugust 3, 2023 | finance.yahoo.comXenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Corporate UpdateJuly 23, 2023 | finance.yahoo.com11 Best Healthcare Stocks Under $50July 17, 2023 | msn.comRBC Capital Reiterates Xenon Pharmaceuticals (XENE) Outperform RecommendationJuly 17, 2023 | markets.businessinsider.comExpert Ratings for Xenon PharmaceuticalsJune 15, 2023 | markets.businessinsider.comGuggenheim Sticks to Their Buy Rating for Xenon (XENE)June 6, 2023 | finance.yahoo.comXenon Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare ConferenceMay 31, 2023 | finance.yahoo.comXenon Pharmaceuticals to Present at the 2023 Jefferies Healthcare ConferenceMay 30, 2023 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Xenon (XENE)See More Headlines Receive XENE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address XENE Company Calendar Last Earnings8/09/2023Today9/22/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XENE CUSIPN/A CIK1582313 Webwww.xenon-pharma.com Phone(604) 484-3300Fax604-484-3450Employees203Year FoundedN/APrice Target and Rating Average Stock Price Forecast$52.40 High Stock Price Forecast$60.00 Low Stock Price Forecast$47.00 Forecasted Upside/Downside+49.0%Consensus RatingBuy Rating Score (0-4)3.09 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($2.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-125,370,000.00 Net MarginsN/A Pretax Margin-123,568.95% Return on Equity-23.32% Return on Assets-22.32% Debt Debt-to-Equity RatioN/A Current Ratio19.34 Quick Ratio19.34 Sales & Book Value Annual Sales$9.43 million Price / Sales239.25 Cash FlowN/A Price / Cash FlowN/A Book Value$11.54 per share Price / Book3.05Miscellaneous Outstanding Shares64,150,000Free Float60,663,000Market Cap$2.26 billion OptionableOptionable Beta1.34 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Ian C. Mortimer C.M.A. (Age 47)CPA, CMA, CPA, M.B.A., MBA, Pres, CEO & Director Comp: $973.76kMs. Sherry Aulin (Age 40)Chief Financial Officer Comp: $3.03MMs. Andrea DiFabio J.D. (Age 55)Chief Legal Officer & Corp. Sec. Comp: $200.51kDr. Christopher E. Von Seggern M.B.A. (Age 44)M.P.H., M.P.H. M.B.A, Ph.D., Chief Commercial Officer Comp: $618.07kDr. Christopher John Kenney M.D. (Age 52)Chief Medical Officer Comp: $684.22kMs. Shelley McCloskey B.A. (Age 63)Exec. VP of HR Dr. Robin P. Sherrington Ph.D. (Age 62)Exec. VP of Strategy & Innovation Dr. James R. Empfield Ph.D. (Age 62)Exec. VP of Drug Discovery Ms. Sheila M. Grant M.B.A.M.Sc., MBA, Exec. VP of R&D OperationsMore ExecutivesKey CompetitorsGalapagosNASDAQ:GLPGSchrödingerNASDAQ:SDGRAmphastar PharmaceuticalsNASDAQ:AMPHZai LabNASDAQ:ZLABHarmony BiosciencesNASDAQ:HRMYView All CompetitorsInsiders & InstitutionsBarclays PLCBought 9,079 shares on 9/21/2023Ownership: 0.014%Perceptive Advisors LLCSold 608,797 shares on 8/24/2023Ownership: 1.907%Dawn SvoronosSold 25,000 sharesTotal: $967,500.00 ($38.70/share)Affinity Asset Advisors LLCSold 29,624 shares on 8/21/2023Ownership: 0.094%California State Teachers Retirement SystemBought 3,167 shares on 8/21/2023Ownership: 0.069%View All Insider TransactionsView All Institutional Transactions XENE Stock - Frequently Asked Questions Should I buy or sell Xenon Pharmaceuticals stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" XENE shares. View XENE analyst ratings or view top-rated stocks. What is Xenon Pharmaceuticals' stock price forecast for 2023? 11 Wall Street analysts have issued twelve-month price objectives for Xenon Pharmaceuticals' shares. Their XENE share price forecasts range from $47.00 to $60.00. On average, they expect the company's stock price to reach $52.40 in the next year. This suggests a possible upside of 49.0% from the stock's current price. View analysts price targets for XENE or view top-rated stocks among Wall Street analysts. How have XENE shares performed in 2023? Xenon Pharmaceuticals' stock was trading at $39.43 at the beginning of 2023. Since then, XENE stock has decreased by 10.8% and is now trading at $35.17. View the best growth stocks for 2023 here. When is Xenon Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our XENE earnings forecast. How were Xenon Pharmaceuticals' earnings last quarter? Xenon Pharmaceuticals Inc. (NASDAQ:XENE) issued its quarterly earnings data on Wednesday, August, 9th. The biopharmaceutical company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.69) by $0.03. Xenon Pharmaceuticals's revenue was down 100.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.55) EPS. What ETFs hold Xenon Pharmaceuticals' stock? ETFs with the largest weight of Xenon Pharmaceuticals (NASDAQ:XENE) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO) and BNY Mellon Innovators ETF (BKIV).First Trust Multi-Manager Small Cap Opportunities ETF (MMSC). What other stocks do shareholders of Xenon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xenon Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Corbus Pharmaceuticals (CRBP), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Viking Therapeutics (vktx), Sangamo Therapeutics (SGMO), Arbutus Biopharma (ABUS), OPKO Health (OPK) and Spectrum Pharmaceuticals (SPPI). What is Xenon Pharmaceuticals' stock symbol? Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE." Who are Xenon Pharmaceuticals' major shareholders? Xenon Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Driehaus Capital Management LLC (7.42%), Polar Capital Holdings Plc (4.71%), Braidwell LP (2.85%), Perceptive Advisors LLC (1.91%), BlackRock Inc. (1.56%) and Nicholas Investment Partners LP (1.24%). Insiders that own company stock include Christopher John Kenney, Dawn Svoronos, Frank A Holler, Gary Patou, Ian Mortimer, James R Empfield, Seggern Christopher Von, Sherrington Robin and Simon N Pimstone. View institutional ownership trends. How do I buy shares of Xenon Pharmaceuticals? Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Xenon Pharmaceuticals' stock price today? One share of XENE stock can currently be purchased for approximately $35.17. How much money does Xenon Pharmaceuticals make? Xenon Pharmaceuticals (NASDAQ:XENE) has a market capitalization of $2.26 billion and generates $9.43 million in revenue each year. The biopharmaceutical company earns $-125,370,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. How many employees does Xenon Pharmaceuticals have? The company employs 203 workers across the globe. How can I contact Xenon Pharmaceuticals? Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The official website for the company is www.xenon-pharma.com. The biopharmaceutical company can be reached via phone at (604) 484-3300, via email at investors@xenon-pharma.com, or via fax at 604-484-3450. This page (NASDAQ:XENE) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.